Evaluation of Protein in the Urine in Patients Receiving Bevacizumab
| Status: | Completed |
|---|---|
| Conditions: | Colorectal Cancer, Cancer, Endocrine |
| Therapuetic Areas: | Endocrinology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 10/21/2012 |
| Start Date: | November 2007 |
| End Date: | January 2011 |
| Contact: | Sachin Shah, Pharm.D. |
| Email: | sachin.shah@ttuhsc.edu |
| Phone: | 214-372-5300 |
An Evaluation of Proteinuria in Patients Receiving Shortened Infusions of Bevacizumab
This is a clinical research study to look at the incidence of proteinuria (a condition in
which urine contains an abnormal amount of protein) caused by shortened infusions (given
into the vein over 10 or 15 minutes) of bevacizumab (a medication prescribed for colon,
lung, or breast cancer). There are currently no published studies or clinical data looking
at how safe shortened infusions of bevacizumab are in relationship to the side effect of
proteinuria. We hypothesis that shortened infusions of bevacizumab will result in an
increased risk for proteinuria compared to the standard infusions of this agent.
Inclusion Criteria:
- Patients must be 18 years older
- Patients must be receiving his/her first dose of bevacizumab
- Patients must sign an informed consent
Exclusion Criteria:
- Patients receiving > 10 mg/kg doses of bevacizumab
We found this trial at
3
sites
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials